As small molecule agonists of Toll-like receptors (TLR) 7 and 8 exhibits superior anti-tumour activity, resiquimod (R848), as a TLR7/8 agonist, has more significant induction of cytokine secretion and macrophage activation than imiquimod, a TLR7/8 agonist approved by the US Food and Drug Administration (FDA). This evidence concerns the gene TLR7 and neoplasm.